Nanosizing - Oral formulation development and biopharmaceutical evaluation

Advanced Drug Delivery Reviews

Volumn 59, Issue 7, 2007, Pages 631-644

  Kesisoglou, Filippos ^a   Panmai, Santipharp ^a   Wu, Yunhui ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bioavailability enhancement; Dissolution; Formulation; Nanoparticle; Nanosizing; Nanosuspension

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS (API); DISSOLUTION RATES; DRUG DEVELOPMENT; NANOSIZING; NANOSUSPENSION;

DISSOLUTION; NANOPARTICLES; PARTICLE SIZE; SOLUBILITY;

DRUG PRODUCTS;

1 [4 (5 BROMO 2 PYRIMIDINYLOXY) 3 CHLOROPHENYL] 3 (2 NITROBENZOYL)UREA; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; AMPHOTERICIN B; ANTIVIRUS AGENT; APREPITANT; CARBENDAZIM; CILOSTAZOL; CLOFAZIMINE; CYCLOSPORIN A; DANAZOL; FENOFIBRATE; ITRACONAZOLE; MEGESTROL ACETATE; NANOPARTICLE; NAPROXEN; PACLITAXEL; PG 301029; RAPAMYCIN; STABILIZING AGENT; TRIGLIDE; UCB 354403; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VISCOSITY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG EVALUATION; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 34548049483     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.05.003     Document Type: Review

References (46)

1. Lipinski C. Poor aqueous solubility - an industry wide problem in drug discovery. Am. Pharm. Rev. 5 (2002) 82-85
2. Noyes A., and Whitney W. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 19 (1897) 930-934
3. Nernst W. Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen. Z. Phys. Chem. 47 1 (1904) 52-55
4. Brunner E. Reaktionsgeschwindigkeit in heterogenen Systemen. Z. Phys. Chem. 47 1 (1904) 56-102
5. Patravale V.B., Date A.A., and Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 56 7 (2004) 827-840
6. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., Shelukar S., Kwei G., and Storey D. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285 1-2 (2004) 135-146
7. Mosharraf M., and Nystrom C. The effect of particle size and shape on the surface specific dissolution rate of micronized practically insoluble drugs. Int. J. Pharm. 122 (1995) 35-47
8. Muller R.H., and Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int. J. Pharm. 160 (1998) 229-237
9. Keck C.M., and Muller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 62 1 (2006) 3-16
10. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3 9 (2004) 785-796
11. Merisko-Liversidge E., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18 2 (2003) 113-120
12. Muller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 1 (2001) 3-19
13. Hunter R.J. Foundations of Colloid Science. 2nd ed. (2001), Oxford University Press, New York
14. Jia L., Wong H., Cerna C., and Weitman S.D. Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm. Res. 19 8 (2002) 1091-1096
15. Hecq J., Deleers M., Fanara D., Vranckx H., Boulanger P., Le Lamer S., and Amighi K. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur. J. Pharm. Biopharm. 64 3 (2006) 360-368
16. Kayser O., Olbrich C., Yardley V., Kiderlen A.F., and Croft S.L. Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 254 1 (2003) 73-75
17. Abdelwahed W., Degobert G., Stainmesse S., and Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev. 58 15 (2006) 1688-1713
18. Allen T. Particle Size Measurement. 5th ed. (2004), Springer
19. Panmai S., and Deshpande S. Development of nanoformulations: selection of polymeric stabilizers based on adsorption isotherm. PMSE Preprints (2003)
20. Stenger F., Mende S., Schwedes J., and Peukert W. Nanomilling in stirred media mills. Chem. Eng. Sci. 60 16 (2005) 4557-4565
21. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., and Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 111 1-2 (2006) 56-64
22. Yu L.X., Lipka E., Crison J.R., and Amidon G.L. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Deliv. Rev. 19 3 (1996) 359-376
23. Jia L., Wong H., Wang Y., Garza M., and Weitman S.D. Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle. J Pharm. Sci. 92 1 (2003) 161-172
24. Euler D., Frech P., Karki S., Cowden C., Pearce G., Mehta P., Lindemann C., Byway P., Wang M., Gibson T., Cheng Y., Kwei G., and Rose J., Influence of physicochemical properties and intestinal region on the absorption of 3-fluoro-2-pyrimidylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, a water insoluble thrombin inhibitor, in dogs. Int. J. Pharm. 275 1-2 (2004) 19-27
25. Lui C.Y., Amidon G.L., Berardi R.R., Fleisher D., Youngberg C., and Dressman J.B. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci. 75 3 (1986) 271-274
26. Johnson J.L., He Y., Jain A., and Yalkowsky S.H. Improving cyclodextrin complexation of a new antihepatitis drug with glacial acetic acid. AAPS PharmSciTech 7 1 (2006) E18
27. Langguth P., Hanafy A., Frenzel D., Grenier P., Nhamias A., Ohlig T., Vergnault G., and Spahn-Langguth H. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev. Ind. Pharm. 31 3 (2005) 319-329
28. Kocbek P., Baumgartner S., and Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm. 312 1-2 (2006) 179-186
29. Hu J., Johnston K.P., and Williams III R.O. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur. J. Pharm. Sci. 20 3 (2003) 295-303
30. Vaughn J.M., McConville J.T., Crisp M.T., Johnston K.P., and Williams III R.O. Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies. Drug Dev. Ind. Pharm. 32 5 (2006) 559-567
31. Muller R.H., Runge S., Ravelli V., Mehnert W., Thunemann A.F., and Souto E.B. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 317 1 (2006) 82-89
32. Majumdar A.K., Howard L., Goldberg M.R., Hickey L., Constanzer M., Rothenberg P.L., Crumley T.M., Panebianco D., Bradstreet T.E., Bergman A.J., Waldman S.A., Greenberg H.E., Butler K., Knops A., De Lepeleire I., Michiels N., and Petty K.J. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J. Clin. Pharmacol. 46 3 (2006) 291-300
33. Rapamune® Prescribing Information (2006), Wyeth Pharmaceuticals, Inc.
34. Megace® ES Prescribing Information (2005), Par Pharmaceutical Companies, Inc.
35. (R) to be Taken With or Without Food (2004), Abbott Laboratories Press Release
36. TriCor® Prescribing Information (2004), Abbott Laboratories
37. Triglide™ Prescribing Information (2005), First Horizon Pharmaceutical Corporation
38. Date A.A., and Patravale V.B. Current strategies for engineering drug nanoparticles. Curr. Opin. Colloid Interface Sci. 9 3-4 (2004) 222-235
39. Gursoy R.N., and Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58 3 (2004) 173-182
40. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 11 Suppl 2 (2000) S93-S98
41. Mehnert W., and Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47 2-3 (2001) 165-196
42. Scholer N., Krause K., Kayser O., Muller R.H., Borner K., Hahn H., and Liesenfeld O. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother. 45 6 (2001) 1771-1779
43. Peters K., Leitzke S., Diederichs J.E., Borner K., Hahn H., Muller R.H., and Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 45 1 (2000) 77-83
44. Kayser O. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages. Int. J. Pharm. 196 2 (2000) 253-256
45. Mouton J.W., van Peer A., de Beule K., Van Vliet A., Donnelly J.P., and Soons P.A. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob. Agents Chemother. 50 12 (2006) 4096-4102
46. Vaughn J.M., McConville J.T., Burgess D., Peters J.I., Johnston K.P., Talbert R.L., and Williams R.O. Single dose and multiple dose studies of itraconazole nanoparticles. Eur. J. Pharm. Biopharm. 63 2 (2006) 95-102